Tonsillar Cytokine Expression After Allergen and/or Virus Intervention

NCT01924208 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2016-04-21

No results posted yet for this study

Summary

Hypotheses

1. Immunotherapy induces tolerogenic effects to allergens in T cell regulation in tonsils.
2. Influenza vaccination induces a strong interferon response and decreases Th2 response in tonsils.
3. Influenza vaccination as an adjuvant on immunotherapy induces a better response to immunotherapy.

Conditions

  • Healthy

Interventions

BIOLOGICAL

Timothy, Phleum pretense

Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .

BIOLOGICAL

Live attenuated influenza virus

Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).

PROCEDURE

Timothy + attenuated influenza virus

Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).

Sponsors & Collaborators

  • Academy of Finland

    collaborator OTHER
  • Juselius Foundation, Helsinki, Finland

    collaborator UNKNOWN
  • Foundation for Paediatric Research, Finland

    collaborator OTHER
  • EVO special government transfers, Turku, Finland

    collaborator UNKNOWN
  • Turku University Hospital

    lead OTHER_GOV

Principal Investigators

  • Tuomas Jartti, M.D. · Dept of Pediatrics, Turku University Hospital, Turku, Finland.

  • Cezmi Akdis, M.D., prof · Swiss Institute of Allergy and Asthma Research (SIAF), University of Zürich, Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01924208 on ClinicalTrials.gov